The results of preclinical studies from autoimmune animal models are promising, and several phase 1 and phase 2 clinical trials with BTK inhibitors were initiated in patients with immune disorders, such as RA, SLE, SM, PV, AIHA, ITP, and GVHD. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.